Takara Bio Wins Approval for Share Consolidation and June Delisting from TSE Prime

An update from Takara Bio Inc. ( (JP:4974) ) is now available.

Takara Bio Inc. secured shareholder approval at an extraordinary general meeting for a massive share consolidation, abolishing share unit provisions and amending its articles of incorporation, effectively reducing 120,415,300 common shares to just six. This restructuring will result in the company’s stock falling under Tokyo Stock Exchange delisting criteria, with trading on the Prime Market set to cease on June 12, 2026 and the move aligning with a broader plan to make Takara Holdings the sole shareholder.

Under the approved plan, all shareholders other than Takara Holdings will see their holdings converted into fractional shares, which will be aggregated and sold, with cash proceeds distributed proportionally. Subject to court approval, these fractional shares are expected to be sold to Takara Holdings at a price designed to mirror the recent tender offer level, effectively cashing out minority investors and completing Takara Bio’s transition to a wholly owned subsidiary, thereby removing public market access to its shares.

The most recent analyst rating on (JP:4974) stock is a Hold with a Yen940.00 price target. To see the full list of analyst forecasts on Takara Bio Inc. stock, see the JP:4974 Stock Forecast page.

More about Takara Bio Inc.

Takara Bio Inc. is a Japan-based biotechnology company listed on the Tokyo Stock Exchange Prime market, focusing on life science research tools and biopharmaceutical development. The company operates under the umbrella of Takara Holdings and targets global researchers and healthcare markets with its genomic, cell and gene therapy, and related bioengineering products and services.

Average Trading Volume: 614,117

Technical Sentiment Signal: Sell

Current Market Cap: Yen137.6B

Learn more about 4974 stock on TipRanks’ Stock Analysis page.